Fig. 2From: PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trialKaplan-Meier plot of 5-year invasive disease-free survival for patients with PIK3CA-altered tumors (correlative cohort)Back to article page